tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Centessa initiated with a Buy at Truist

Truist initiated coverage of Centessa (CNTA) with a Buy rating and $30 price target The firm sees “significant upside potential” for ORX750 in Narcolepsy and Idiopathic Hypersomnia, says the analyst, who views orexin-2 receptor agonist’s such as ORX750 as “poised to become the new standard-of-care.” While acknowledging that ORX750 is slightly behind competitors, the analyst thinks the drug has the potential to differentiate on safety, efficacy and dosing convenience.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1